Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus M PREDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus M PREDROL.
DEXAIR vs M-PREDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect.
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid